| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BNP; NPPB |
| Entrez GeneID | 4879 |
| clone | 8D5B4C11 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide corresponding to aa (Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser) of human BNP, conjugated to KLH. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是关于BNP抗体的3篇代表性文献及其摘要概括：
---
1. **文献名称**：Development of a High-Sensitivity Sandwich Immunoassay for Brain Natriuretic Peptide in Human Plasma
**作者**：Smith A, et al.
**摘要**：本研究报道了一种基于双抗体夹心法的高灵敏度BNP检测技术，通过筛选特异性单克隆抗体对，显著提升了检测下限(可达1 pg/mL)，为早期心力衰竭诊断提供可靠工具。
---
2. **文献名称**：Interference of Heterophilic Antibodies in BNP Immunoassays: Mechanisms and Clinical Implications
**作者**：Zhang L, et al.
**摘要**：探讨了异嗜性抗体对商用BNP免疫检测平台的干扰现象，提出通过添加阻断剂和抗体表位优化策略降低假阳性/假阴性风险，强调临床结果解读时需注意干扰因素。
---
3. **文献名称**：Autoantibodies Against BNP in Patients with Heart Failure: Prevalence and Prognostic Value
**作者**：Tanaka K, et al.
**摘要**：首次发现约8%的心衰患者血清中存在BNP自身抗体，其存在与BNP检测值偏低和不良预后显著相关，提示自身免疫反应可能影响BNP代谢及生物活性。
---
注：以上文献信息为模拟生成，实际引用时请核实具体文献来源及准确性。建议通过PubMed或Web of Science以"BNP antibody"、"immunoassay"、"autoantibody"为关键词检索最新研究。
**Background of BNP Antibodies**
B-type natriuretic peptide (BNP) is a cardiac hormone primarily secreted by the ventricles in response to myocardial stretch or volume overload. It plays a key role in regulating blood pressure, fluid balance, and cardiovascular homeostasis by promoting vasodilation, natriuresis, and diuresis. Elevated BNP levels are strongly associated with heart failure (HF), making it a critical biomarker for diagnosing and monitoring disease severity.
BNP antibodies are essential tools in immunoassays designed to quantify BNP concentrations in clinical settings. These antibodies, often monoclonal, specifically recognize epitopes on the BNP molecule or its precursor, proBNP. Since BNP coexists with its inactive fragment (NT-proBNP) and undergoes enzymatic degradation, assay specificity is vital to avoid cross-reactivity and ensure accurate diagnosis.
The development of high-affinity BNP antibodies has improved the reliability of point-of-care and laboratory-based tests. However, challenges remain, including standardization across assays, interference from heterophilic antibodies, and variability in BNP stability. Despite these issues, BNP antibody-based assays are widely used to guide HF management, assess prognosis, and tailor therapies.
Research continues to refine antibody design, exploring recombinant or engineered variants to enhance sensitivity and reduce interassay variability. Additionally, therapeutic antibodies targeting BNP pathways are under investigation for potential cardiovascular applications. Overall, BNP antibodies remain indispensable in bridging cardiovascular pathophysiology with clinical diagnostics and treatment.
(Word count: 247)
×
